133 related articles for article (PubMed ID: 36737865)
1. The influence of Medicare Part D on the list pricing of brand drugs.
Ippolito BN; Levy JF
Health Serv Res; 2023 Aug; 58(4):948-952. PubMed ID: 36737865
[TBL] [Abstract][Full Text] [Related]
2. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
3. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
4. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
5. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
6. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
Lakdawalla D; Li M
JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications.
Mattingly TJ; Anderson GF; Levy JF
JAMA Health Forum; 2023 Jun; 4(6):e231317. PubMed ID: 37294584
[TBL] [Abstract][Full Text] [Related]
8. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
9. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
10. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
11. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
12. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
13. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
14. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
15. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
17. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
[TBL] [Abstract][Full Text] [Related]
18. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
19. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
[TBL] [Abstract][Full Text] [Related]
20. Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.
Liu M; MacKenna B; Feldman WB; Walker AJ; Avorn J; Kesselheim AS; Goldacre B
J R Soc Med; 2020 Sep; 113(9):350-359. PubMed ID: 32910868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]